Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations

Journal of Thoracic Oncology

Volumn 8, Issue 7, 2013, Pages

  Morabito, Alessandro ^a   Costanzo, Raffaele ^a   Rachiglio, Anna Maria ^b   Pasquale, Raffaella ^b   Sandomenico, Claudia ^a   Franco, Renato ^c   Montanino, Agnese ^a   De Lutio, Elisabetta ^a   Rocco, Gaetano ^a   Normanno, Nicola ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Centro di Ricerche Oncologiche di Mercogliano CROM   (Italy)

^c Pathologic Service POS Maria Del Popolo Degli Incurabili   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; THYROID TRANSCRIPTION FACTOR 1;

AGED; ALLELE; BONE METASTASIS; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LIVER BIOPSY; LIVER METASTASIS; LUNG LESION; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MALE; MEDIASTINUM LYMPH NODE; MUTATIONAL ANALYSIS; NOTE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SMOKING; TREATMENT RESPONSE;

EID: 84880887864     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318286cc26     Document Type: Article

References (5)

1. Pao W, Chmielecki J. Rational, biologically based treatment of EGFRmutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760-774.
2. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26.
3. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
4. Wu JY, Wu SG, Yang CH, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008;14:4877-4882.
5. Rosell R, Molina MA, Costa C, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011;17:1160-1168.